Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis

References

• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Marra CA, Bansback N, Anis AH, et al. Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clin Rheumatol 2011;30(Suppl 1):S9-18
   PubMedGoogle Scholar
• Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90
   PubMed Web of Science ®Google Scholar
• Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6
   PubMedGoogle Scholar
• Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med Decis Making 2005;25:520-33
   PubMed Web of Science ®Google Scholar
• Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 2005;23:607-18
   Google Scholar
• Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:1-91
   Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guidance on the Use of Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis. London: National Institute for Health and Care Excellence; 2002
   Google Scholar
• National Institute for Health and Care Excellence. The Clinical Effectiveness and Cost-Effectiveness of New Drug Treatments for Rheumatoid Arthritis: Etanercapt and Infliximab. Technology Appraisal No. 36. London: National Institute for Health and Care Excellence; 2002
   Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-229
   Web of Science ®Google Scholar
• Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation. Health Technol Assess 2011;15:1-300
   PubMed Web of Science ®Google Scholar
• Beresniak A, Russell AS, Haraoui B, et al. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007;34:2193-200
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-54
   PubMed Web of Science ®Google Scholar
• Davies A, Cifaldi MA, Segurado OG, et al. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009;36:16-26
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ 2012;15:576-85
   PubMedGoogle Scholar
• Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009;151:612-21
   PubMed Web of Science ®Google Scholar
• Hallinen TA, Soini EJ, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77
   PubMed Web of Science ®Google Scholar
• Kielhorn A, Porter D, Diamantopoulos A, et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008;24:2639-50
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200
   PubMed Web of Science ®Google Scholar
• Krieckaert CLM, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: An evaluation of costs and effects. Ann Rheum Dis 2013;0:1–8. doi:10.1136/annrheumdis-2013-204101
   Google Scholar
• Lekander I, Borgstrom F, Lysholm J, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ 2013;14:863-73
   PubMed Web of Science ®Google Scholar
• Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009;25:181-9
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Kirchhoff T, Wolka D, et al. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ 2010;11:95-104
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Bounthavong M, Mendes MA, et al. Cost utility of tumour necrosis factor-alpha inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Pharmacoeconomics 2012;30:575-93
   PubMed Web of Science ®Google Scholar
• Russell A, Beresniak A, Bessette L, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009;28:403-12
   PubMed Web of Science ®Google Scholar
• Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford) 2011;50:1320-30
   PubMed Web of Science ®Google Scholar
• Soini EJ, Hallinen TA, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15:340-51
   PubMedGoogle Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-32
   PubMed Web of Science ®Google Scholar
• Tanno M, Nakamura I, Ito K, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006;16:77-84
   PubMedGoogle Scholar
• Valle-Mercado C, Cubides MF, Parra-Torrado M, et al. Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia. Rheumatol Int 2013;33:2993-7
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008;35:1745-53
   PubMed Web of Science ®Google Scholar
• Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-46
   PubMed Web of Science ®Google Scholar
• Wu B, Wilson A, Wang FF, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLoS One 2012;7:e47373
   PubMedGoogle Scholar
• Yuan Y, Trivedi D, Maclean R, et al. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ 2010;13:33-41
   PubMedGoogle Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008;47:535-41
   PubMed Web of Science ®Google Scholar
• Lekander I, Kobelt G, Svarvar P, et al. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach. Value Health 2013;16:251-8
   Google Scholar
• Strandberg-Larsen M, Hansen BB, Göthberg M, et al. Outcome differences in algorithms used for indirect mapping of utility values from HAQ-DI: An assessment based on Phase 2a clinical trial data in patients with rheumatoid arthritis after treatment With NNC0109-0012 (Anti-Il-20 MAB). Value Health 2012;15:A476 [Abstract No. PRM490]
   Google Scholar
• Jobanputra P. A clinician’s critique of rheumatoid arthritis health economic models. Rheumatology (Oxford) 2011;50(Suppl 4):iv48-iv52
   PubMedGoogle Scholar
• Bansback N, Marra C, Tsuchiya A, et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963-71
   Google Scholar
• Farragher TM, Lunt M, Bunn DK, et al. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007;66:486-92
   Google Scholar
• Kessler RC, Maclean JR, Petukhova M, et al. The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples. J Occup Environ Med 2008;50:88-98
   PubMedGoogle Scholar
• Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82
   PubMed Web of Science ®Google Scholar
• Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8
   PubMed Web of Science ®Google Scholar
• Spinner DS, Birt J, Walter JW, et al. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res 2013;5:69-85
   PubMedGoogle Scholar
• The EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 2007;26:597-612
   PubMed Web of Science ®Google Scholar
• Adams R, Walsh C, Veale D, et al. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010;28:477-87
   PubMedGoogle Scholar
• Salaffi F, Carotti M, Ciapetti A, et al. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:661-71
   PubMed Web of Science ®Google Scholar
• Sorensen J, Linde L, Ostergaard M, et al. Quality-adjusted life expectancies in patients with rheumatoid arthritis—comparison of index scores from EQ-5D, 15D, and SF-6D. Value Health 2012;15:334-9
   PubMed Web of Science ®Google Scholar
• Buitinga L, Braakman-Jansen LM, Taal E, et al. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res (Hoboken) 2012;64:826-32
   Google Scholar
• Beaton DE, Tang K, Gignac MA, et al. Reliability, validity, and responsiveness of five at-work productivity measures in patients with rheumatoid arthritis or osteoarthritis. Arthritis Care Res (Hoboken) 2010;62:28-37
   PubMed Web of Science ®Google Scholar
• Burton W, Morrison A, Maclean R, et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006;56:18-27
   PubMed Web of Science ®Google Scholar
• Escorpizo R, Bombardier C, Boonen A, et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80
   PubMed Web of Science ®Google Scholar
• Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1083-90
   PubMed Web of Science ®Google Scholar